Evie Carchman, MD, FACS

Tenured Associate Professor

  • Division of Colorectal Surgery

carchman@surgery.wisc.edu
(608) 263-4224

  • Administrative Assistant: (608) 263-2521

Clinical Science Center
600 Highland Avenue
Madison, WI 53792-7375

Education

  • MD, Medical College of Virginia at Virginia Commonwealth University, Richmond, VA, 2006
  • General Surgery Residency, University of Pittsburgh Medical Center, Pittsburgh, PA, 2013
  • Colon and Rectal Surgery Fellowship, Cleveland Clinic, Cleveland, OH, 2014

Clinical Specialties

Dr. Evie Carchman is a fellowship-trained colon and rectal surgeon. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.

Research Interests

Dr. Carchman’s Research Lab >>

Dr. Carchman’s research interests focus on the pathogenesis and treatment of anal cancer. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.

Recent Publications

  • Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease.
    Gunder LC, Johnson HR, Yao E, Moyer TH, Green HA, Sherer N, Zhang W, Carchman EH
    Viruses 2023 Apr 20; 15(4)
    [PubMed ID: 37112993]

  • Treating acute diverticulitis in pre- and post-solid-organ transplant patients: a single-institution cohort study.
    Klos CL, Bath NM, Carchman E, Leverson G, Lawson E, Sanger CB, King R, Heise C
    Colorectal Dis 2023 Jun; 25(6): 1238-1247
    [PubMed ID: 36945080]

  • The Use of the Protease Inhibitor, Saquinavir, to Treat Anal Cancer Spheroids Derived From Human Papillomavirus Transgenic Mice.
    Johnson HR, Gunder LC, Leverson GE, Carchman EH
    Dis Colon Rectum 2023 Mar 01; 66(3): 360-365
    [PubMed ID: 36599112]

  • Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.
    Gunder LC, Moyer TH, Johnson HR, Auyeung AS, Leverson GE, Zhang W, Matkowskyj KA, Carchman EH
    J Surg Res 2023 Feb; 282: 137-146
    [PubMed ID: 36274448]

  • The use of a topical protease inhibitor, Saquinavir, to alleviate mouse papillomavirus-mediated anal disease.
    Gunder LC, Johnson HR, Green HA, Bilger A, Moyer TH, Zhang W, Ziolkowski MR, Bertrang PA, Carchman EH
    Virology 2022 Nov; 576: 96-104
    [PubMed ID: 36206607]

All Publications on PubMed